Option chain shows key data for ProAssurance's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ProAssurance.

ProAssurance (NYSE:PRA) Stock, Option Chain

ProAssurance

ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.

Earnings

News

Dividends

Price Target

Buybacks

Small Cap

Markets

Analyst Ratings

Trading Ideas

Insurance

AMSF

AMERISAFE, Inc. (NASDAQ: AMSF) is currently considered expensive on a relative basis, with the stock trading at a 22X forward 12-month price-to-earnings (P/E) ratio, which is at a premium compared with its five-year median of 20.21X and the Zacks Insurance - Accident and Health average of 13.36X.

Is AMERISAFE Stock a Pricey Pick or a Hidden Gem for Your Portfolio?

Earnings Beats

Mid Cap

Federal Reserve

HRTG

NMIH

Shares of NMI Holdings (NASDAQ: NMIH) have rallied 28.9% year to date, outperforming the industry&#39;s increase of 24.6%, the Finance sector&#39;s increase of 11.6% and the S&amp;P 500 composite&#39;s rise of 17.5%.

NMI Holdings Surges 29% YTD: Will the Rally Last?

AMBC

ProAssurance Corporation (NYSE: PRA) is set to report its second-quarter 2024 results on Aug 8, after the closing bell.

ProAssurance Q2 Earnings: Profit Climb or Slippery Slope?

ProAssurance Corp

PRA Group Inc

PRODUCTIVITY TECHS CORP by Productivity Technologies Corp.

Productivity Technologies Corp

Northern Lights Fund Trust III PlanRock Alternative Growth ETF

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

NEOS ETF Trust FIS Christian Stock Fund

<h3>Gainers</h3>
<ul>
<li><strong>XChange Tec</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) stock increased by 27.4% to $1.44 during Monday's pre-market session. The market value of their outstanding shares is at $162.1 million. </li>
<li><strong>Stock Yards Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) stock moved upwards by 27.07% to $84.62. The market value of their outstanding shares is at $2.4 billion. </li>
<li><strong>S&amp;T Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBA#NASDAQ">STBA</a>) shares increased by 26.07% to $44.67. The market value of their outstanding shares is at $1.7 billion. </li>
<li><strong>Hamilton Lane</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) stock moved upwards by 12.46% to $157.18. The market value of their outstanding shares is at $6.5 billion. </li>
<li><strong>Powell Max</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) shares moved upwards by 9.72% to $2.03. The market value of their outstanding shares is at $29.8 million. </li>
<li><strong>Greenpro Capital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNQ#NASDAQ">GRNQ</a>) stock increased by 9.52% to $2.07. The company's market cap stands at $15.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>FirstCash Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) shares declined by 29.6% to $75.08 during Monday's pre-market session. The company's market cap stands at $3.3 billion. </li>
<li><strong>RenaissanceRe Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) shares declined by 11.29% to $221.83. The market value of their outstanding shares is at $11.5 billion. </li>
<li><strong>ProAssurance</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) stock decreased by 9.98% to $12.81. The company's market cap stands at $655.3 million. </li>
<li><strong>Vinci Partners Inv</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) shares fell 8.5% to $8.51. The company's market cap stands at $549.9 million. </li>
<li><strong>Hennessy Advisors</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNNA#NASDAQ">HNNA</a>) stock decreased by 8.39% to $10.6. The market value of their outstanding shares is at $82.4 million. </li>
<li><strong>eHealth</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) shares fell 8.33% to $9.03. The company's market cap stands at $267.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

EHTH

FCFS

GRNQ

HLNE

HNNA

PMAX

STBA

SYBT

VINP

12 Financials Stocks Moving In Monday's Pre-Market Session

<p>Truist Securities  analyst Mark Hughes   maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Hold and raises the price target from $14 to $18.</p>


Truist Securities Maintains Hold on ProAssurance, Raises Price Target to $18

WIIM

ProAssurance shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

<p>ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent.  The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent.  This is a 17.67 percent increase over sales of $242.42 million the same period last year.</p>


Earnings Misses

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

<p><strong>AMERISAFE, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amsf#NASDAQ">AMSF</a>) is currently considered expensive on a relative basis, with the stock trading at a 22X forward 12-month price-to-earnings (P/E) ratio, which is at a premium compared with its five-year median of 20.21X and the Zacks&nbsp;Insurance - Accident and Health average of 13.36X. A premium valuation generally indicates that the market has strong confidence in the company&#39;s prospects. However, this necessitates scrutiny to determine if this higher price is warranted.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a5/80818.jpg?v=1155545738" style="border-style:solid; border-width:1px; height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>In comparison, other insurers like&nbsp;<strong>Employers Holdings, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eig#NYSE">EIG</a>) and&nbsp;<strong>ProAssurance Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>) are cheaper at 13.30X and 19.72X, respectively.</p>
<p>A brief analysis is needed to determine whether AMSF&#39;s premium valuation is justified based on its growth prospects and fundamentals.</p>
<p>Let&#39;s delve deeper.</p>
<p>Incorporated in 1985 and headquartered in DeRidder, LA, AMERISAFE currently has a market cap of $909.9 million. It is well positioned for growth, leveraging rising investment income and a robust balance sheet.</p>
<p>AMSF&#39;s extensive experience in hazardous industries and a high policy retention rate are major positives. Its cost-saving initiatives are expected to support its bottom line. Last year, it lowered loss and loss adjustment expenses by 2.7%.</p>
<p>The long time lag between receiving premiums and settling claims allows the company to invest funds for extended periods, compounding returns more effectively than insurers with quicker claim payouts, thereby boosting its investment income potential. Last year, it recorded a net investment income of $31.3 million, which advanced by 15.1%, resulting from increased fixed-income reinvestment rates. The first half of 2024 also witnessed higher reinvestment rates.</p>
<p>AMSF&#39;s solid balance sheet, with no debt and $884.2 million in investments and cash as of June 30, 2024, supports initiatives to boost shareholder value. The company raised its quarterly dividend by 8.8% in February 2024, continuing its steady dividend payments since 2013. In the second quarter, AMERISAFE repurchased $4.1 million worth of shares, with $6.3 million remaining in its buyback program as of June 30.</p>
<h2>Should Investors Pay the Premium for AMSF?</h2>
<p>The factors mentioned above have contributed to AMERISAFE&#39;s premium valuation, reflecting strong investor confidence in its future growth and profitability. As a result, investors are willing to pay a higher price for the stock, anticipating that it will outperform both its industry peers and the broader market in the coming months.</p>
<p>However, uncertainty surrounds the stock due to AMERISAFE&#39;s continuous decline in net premiums earned over the past five years. If this trend persists, it could potentially impede the company&#39;s ability to enhance its profits. The Zacks Consensus Estimate for 2024 earnings is pegged at $2.40 per share, indicating a 17.5% year-over-year decline. The same for 2025 signals a further 12.5% fall.</p>
<p>Also, AMERISAFE has faced a downward trend in free cash flow from 2018 to 2022, indicating potential operational challenges. While it saw a 12.2% increase in 2023, the sustainability of this growth is uncertain. In the trailing 12 months, free cash flow dropped sharply by 56.7%, raising concerns about the company&#39;s long-term financial health.</p>
<p>Despite these headwinds, the company&#39;s overall outlook remains positive. Leading brokers have raised AMSF&#39;s short-term price target by 12.47% from its recent closing price of $47.72, with the highest target set at $65, representing a potential upside of 36.21%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/80819.jpg?v=1182891382" style="border-style:solid; border-width:1px; height:315px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Existing investors should hold onto AMERISAFE stock to capitalize on its upward price movement. However, new investors might want to wait for a better entry point. Currently, the stock has a Zacks Rank #3 (Hold) and appears overvalued, suggesting that it may not be the ideal time to buy. Waiting for a more attractive valuation could present a better opportunity to invest.</p>
<p><a href="https://www.zacks.com/stock/news/2347764/is-amerisafe-stock-a-pricey-pick-or-a-hidden-gem-for-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347764">To read this article on Zacks.com click here.</a></p>


<p>Shares of <strong>NMI Holdings </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmih#NASDAQ">NMIH</a>) have rallied 28.9% year to date, outperforming the industry&#39;s increase of 24.6%, the Finance sector&#39;s increase of 11.6% and the S&amp;P 500 composite&#39;s rise of 17.5%.</p>
<p>An improving mortgage insurance portfolio, higher new insurance written volume, a comprehensive reinsurance program, its solid capital position and effective capital deployment drive this Zacks Rank #2 (Buy) stock.</p>
<p>This mortgage insurer has a decent history of delivering surprises in the last six quarters.</p>
<p>NMIH&#39;s return on equity (ROE) for the trailing 12 months is 18.3%, better than the industry average of 8%. This reflects efficiency in utilizing its shareholders&#39; funds. It targets 13% ROE over the medium term.</p>
<p>Also, the return on invested capital in the trailing 12 months was 14.8%, better than the industry average of 6.1%, which reflected the insurer&#39;s efficiency in utilizing funds to generate income.</p>
<p>The Zacks Consensus Estimate for NMI Holdings&#39; 2024 and 2025 earnings has moved 4.7% and 2.6% north, respectively, in the past 30 days, reflecting analyst optimism.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/52/74926.jpg?v=778876063" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Can NMIH Retain the Momentum?</h3>
<p>Per the Federal Reserve, the U.S. residential mortgage market is one of the largest in the world, with nearly $13 trillion of mortgage debt outstanding as of Dec 31, 2023, and includes both primary and secondary components. NMIH stands to gain from new business opportunities from a growing mortgage insurance market.&nbsp;NMI Holdings&#39; mortgage insurance portfolio is expected to create a strong foundation for future earnings.</p>
<p>Growth in monthly and single premium policy production is tied to the increased penetration of existing customer accounts. New customer account activation will also drive results.</p>
<p>In order to enhance its return profile, absorb losses, provide efficient growth capital and mitigate the impact of credit volatility, NMIH has a comprehensive reinsurance program for its in-force portfolio.</p>
<p>To drive margin expansion, NMIH remains focused on efficiency and expense management.</p>
<p>NMIH engages in share buybacks and has a $124.9 million share repurchase program under its kitty.</p>
<p>All these together should help the insurer continue to generate solid mid-teens shareholders&#39; returns.</p>
<p>The Zacks Consensus Estimate for NMI Holdings&#39; 2024 earnings is pegged at $4.44, which indicates a 15.6% increase from the year-ago reported figure on 11.8% higher revenues of $647.1 million. The consensus estimate for 2025 earnings per share is pegged at $4.69, which implies a 5.6% increase year over year on 6.5% higher revenues of $689 million.</p>
<p>The expected long-term growth rate is pegged at 9.8%. Notably, earnings grew 18.7% in the past five years, better than the industry average of 10.5%. NMI Holdings&#39; superior primary insurance in-force portfolio generates industry-leading growth. &nbsp;</p>
<h3>Attractive Valuation</h3>
<p>NMIH&#39;s shares are trading at a price-to-book multiple of 1.49, lower than the industry average of 1.56. Before valuation expands, it is wise to take a position in the stock.</p>
<p>This insurer has a Value Score of B, reflecting an attractive valuation.&nbsp; Back-tested results have shown that stocks with a Value Score of A or B combined with a Zacks Rank #1 (Strong Buy) or #2 offer superior returns.</p>
<h3>Other Stocks to Consider</h3>
<p>Some other top-ranked stocks from the insurance industry are <strong>Heritage Insurance </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrtg#NYSE">HRTG</a>), <strong>Axis Capital Holdings </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axs#NYSE">AXS</a>) and <strong>ProAssurance Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>), each sporting a Zacks Rank #1 (Strong Buy).</p>
<p>Heritage Insurance earnings surpassed estimates in three of the last four quarters and missed in one, the average beat being 49.15%. Year to date, HRTG has rallied 132.4%.</p>
<p>The Zacks Consensus Estimate for HRTG&#39;s 2024 and 2025 earnings implies 10.3% and 18.1% year-over-year growth, respectively.</p>
<p>Axis Capital earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 94.62%. Year to date, AXS&#39; stock has surged 35.1%.</p>
<p>The Zacks Consensus Estimate for AXS&#39; 2024 and 2025 earnings indicates 8.3% year-over-year growth each.</p>
<p>ProAssurance earnings surpassed estimates in two of the last four quarters and missed in the other two. Year to date, PRA&#39;s stock has lost 2.6%.</p>
<p>The Zacks Consensus Estimate for PRA&#39;s 2024 and 2025 earnings suggests 457.1% and 49.2% year-over-year growth, respectively.</p>
<p><a href="https://www.zacks.com/stock/news/2325241/nmi-holdings-nmih-surges-29-ytd-will-the-rally-last?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2325241">To read this article on Zacks.com click here.</a></p>


<p>Truist Securities  analyst Mark Hughes   maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Hold and lowers the price target from $16 to $14.</p>


Truist Securities Maintains Hold on ProAssurance, Lowers Price Target to $14

ProAssurance shares are trading higher after the company reported better-than-expected Q2 financial results.

<p>ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.10 by 130 percent. This is a 64.29 percent increase over earnings of $0.14 per share from the same period last year.  The company reported quarterly sales of $239.867 million which beat the analyst consensus estimate of $239.598 million by 0.11 percent.  This is a 3.23 percent decrease over sales of $247.862 million the same period last year.</p>


ProAssurance Q2 2024 Adj. EPS $0.23 Beats $0.10 Estimate, Sales $239.867M Beat $239.598M Estimate

<p><strong>ProAssurance Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>) is set to report its second-quarter 2024 results on Aug 8, after the closing bell.</p>
<p>The Zacks Consensus Estimate for second-quarter earnings is currently pegged at 8 cents per share, implying a decline of 50% from the year-ago reported number. The estimate remained stable over the past month. The Zacks Consensus Estimate for second-quarter revenues is currently pegged at almost $273.7 million, suggesting a 3.1% fall from the year-ago actuals.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b7/73610.jpg?v=1011417650" style="border-style:solid; border-width:1px; height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>ProAssurance beat the consensus estimate for earnings in two of the trailing four quarters and missed twice, with the average surprise being negative 42.9%, as you can see below.</p>
<div class="chart_embed">
<h3>ProAssurance Corporation Price and EPS Surprise</h3>
<p><img alt="ProAssurance Corporation Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/76/1723034329.png" style="border-style:solid; border-width:1px; height:310px; width:600px" title="" /></p>
<p>ProAssurance Corporation price-eps-surprise | ProAssurance Corporation Quote</p>
</div>
<h3>Q2 Earnings Whispers</h3>
<p>Our proven model does not conclusively predict an earnings beat for ProAssurance this time around. The combination of a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.</p>
<p><strong>Earnings ESP</strong>: The company has an Earnings ESP of 0.00%. This is because the Most Accurate Estimate currently stands at 8 cents per share, in line with the Zacks Consensus Estimate.</p>
<p><strong>Zacks Rank</strong>: ProAssurance currently carries a Zacks Rank #3.</p>
<p>Now, let&#39;s see how things have shaped up before the second-quarter earnings announcement.</p>
<h3>Q2 Key Predictions</h3>
<p>ProAssurance&#39;s second-quarter results are expected to have been affected by lower premiums, weaker contributions from the segments and deteriorating ratios. The negatives are likely to have been partially offset by growth in investment income.</p>
<p>The Zacks Consensus Estimate for net premiums earned indicates a 5.2% year-over-year decline, whereas our estimate suggests a 6.1% fall. The consensus mark for Specialty P&amp;C Segment&#39;s operating loss is pegged at $14.3 million, while our model estimate stands at a loss of $12.9 million.</p>
<p>Similarly, the consensus estimate for Workers&#39; Compensation operating loss is pegged at $6.4 million, wider than the year-ago level of $2.5 million. Also, the consensus estimate and our model estimate for Segregated Portfolio Cell Reinsurance&#39;s profits indicate around 36% year-over-year fall. The renewal rate is expected to have declined in the second quarter.</p>
<p>The consensus mark for the combined ratio is pegged at 112.35%, while our estimate suggests 112.37% compared with the year-ago level of 108.20%. A higher combined ratio suggests that the company has less premium left after claim settlements.</p>
<p>The consensus mark for the underwriting expense ratio is pegged at 31.62%, while our estimate stands at 31.91% compared with the year-ago level of 31.10%. These factors are expected to have positioned the company for a year-over-year decline in profits, making an earnings beat uncertain.</p>
<p>Nevertheless, higher investment income due to the high-interest rate environment is likely to have provided some breathing room. The Zacks Consensus Estimate for net investment income indicates an 8.9% year-over-year increase, while our estimate suggests 8.1% growth.</p>
<h3>Price Performance</h3>
<p>ProAssurance&#39;sstock has lost 16.2% year to date, against the industry&#39;s rally of 17.3%. The S&amp;P 500 Index registered a 10% gain during this time. In comparison, its peers like <strong>Universal Insurance Holdings, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uve#NYSE">UVE</a>) and <strong>Ambac Financial Group, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ambc#NYSE">AMBC</a>) increased 16.9% and decreased 36.9%, respectively, during the same period.</p>
<h3>YTD Price Performance</h3>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d5/73611.jpg?v=1673120884" style="border-style:solid; border-width:1px; height:310px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>What Should Investors Do Now?</h3>
<p>Given ProAssurance&#39;s cost-control and inorganic growth efforts and rising investment income, current investors may consider holding onto the stock and closely monitoring the upcoming earnings results. The decline in stock price has improved its valuation as compared with the industry average. However, it faces several challenges, including increasing competition, an anticipated decline in premiums and profits and a high leverage ratio. These headwinds suggest that new investors might want to wait and observe how the company navigates these challenges before making any investment decisions.</p>
<p><a href="https://www.zacks.com/stock/news/2318163/proassurance-pra-q2-earnings-profit-climb-or-slippery-slope?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2318163">To read this article on Zacks.com click here.</a></p>


<p><strong>ProAssurance</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>) shares soared 12.6% in the last trading session to close at $13.16. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 4.2% loss over the past four weeks.</p>
<p>Increased optimism around the accelerated growth in new business is driving the stock. This is expected to boost premium levels in the near future. The company&#39;s Specialty P&amp;C Segment and Workers&#39; Compensation Insurance businesses are likely to be key growth drivers. Additionally, the company&#39;s focus on cost-control measures is expected to improve its margins, further enhancing its financial performance.</p>
<p>This medical professional liability insurer is expected to post quarterly earnings of $0.08 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $273.65 million, down 3.1% from the year-ago quarter.</p>
<p>While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.</p>
<p>For ProAssurance, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PRA going forward to see if this recent jump can turn into more strength down the road.</p>
<p>The stock currently carries a Zacks Rank #1 (Strong Buy).</p>
<p>ProAssurance is a member of the Zacks Insurance - Property and Casualty industry. One other stock in the same industry, <strong>Root, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>), finished the last trading session 5.5% lower at $63.40. ROOT has returned 30.3% over the past month.</p>
<p>For Root, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.74. This represents a change of +31.8% from what the company reported a year ago. Root currently has a Zacks Rank of #1 (Strong Buy).</p>
<p><a href="https://www.zacks.com/stock/news/2313219/proassurance-pra-moves-12-6-higher-will-this-strength-last?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2313219">To read this article on Zacks.com click here.</a></p>


ROOT

ProAssurance Moves 12.6% Higher: Will This Strength Last?

<p><strong>First American Financial </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/faf#NYSE">FAF</a>) is poised to grow, given the increased demand among millennials for first-time home purchases. The expansion of its valuation and data businesses, as well as strength in commercial business and technological upgrades, is expected. These, along with solid growth projections, make the Zacks rank #3 (Hold) stock worth retaining.</p>
<h3>An Outperformer</h3>
<p>Shares have gained 8.5% in the past month, outperforming the industry&#39;s growth of 7.6%, the Finance sector&#39;s decline of 1% and the Zacks S&amp;P 500 composite&#39;s increase of 0.7%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ff/71942.jpg?v=482038030" /><br />
Image Source: Zacks Investment Research</p>
<h3>Optimistic Growth Projection</h3>
<p>The Zacks Consensus Estimate for 2024 earnings is pegged at $3.83, indicating an increase of 0.8% on 4.7% higher revenues of $6.3 billion. The consensus estimate for 2025 earnings is pegged at $5.12, indicating an increase of 33.8% on 10.2% higher revenues of $6.9 billion.<br />
We expect 2026 EPS to witness a three-year CAGR of 11.3%.</p>
<h3>Return on Equity</h3>
<p>Return on equity (ROE) is a measure of profitability, reflecting how efficiently a company is utilizing its shareholders&#39; funds. FAF&#39;s trailing 12-month ROE of 8.2% outperformed the industry average of 7.8%. &nbsp;</p>
<h3>Growth Drivers</h3>
<p>An increased demand for first-time home purchases among millennials continues to drive results at First American. It expects housing demand, improving economy and labor markets to drive home price appreciation. Thus, banking on growing leadership in title data, courtesy of proprietary data extraction, sturdy distribution relationships, prudent underwriting and continued investments in technology, FAF remains well poised for long-term growth.</p>
<p>Growing direct premiums, escrow fees and title agent premiums should continue to drive the top line. We expect the 2026 top line to increase at a three-year CAGR of 8.2%.</p>
<p>Strategic initiatives to strengthen its product offerings, intensify the company&#39;s focus on its core business and expand FAF&#39;s valuation and data businesses bode well. Also, the expansion of title plant assets and the upgrade of technology solutions drive increased efficiency.</p>
<h3>Impressive Dividend History and Share Buyback Plans</h3>
<p>First American has a solid track record of dividend increase, with the metric witnessing an eight-year (2016-2024) CAGR of 8.2%. FAF&#39;s dividend yield of 3.9% compares positively with the industry average of 0.3%.</p>
<p>The company also engaged in share buyback and had $210.4 million remaining under its authorization as of Mar 31, 2024.</p>
<h3>Risks</h3>
<p>Despite the upside potential, there are a few factors that investors should keep an eye on. A challenging real estate and mortgage industry weigh on First American. Transaction volumes suffer due to higher mortgage rates and slow inventory growth. A tough mortgage origination market is a concern.</p>
<p>Also, as the Fed intends to lower rates, the company estimates that for each 25-basis point decline in the Fed funds rate, the annualized investment income will decline $15 million. But the ultimate amount will fluctuate depending on the level of cash and escrow balances.</p>
<p>First American&#39;s debt levels have been increasing in the past few years, with the debt-to-capital ratio deteriorating. Its times interest earned compares unfavorably with the industry average.&nbsp;</p>
<h3>Stocks to Consider</h3>
<p>Some top-ranked stocks from the insurance industry are <strong>RLI Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rli#NYSE">RLI</a>), <strong>Palomar Holdings </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>) and <strong>ProAssurance Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>). Each stock presently sports a Zacks Rank&nbsp;#1 (Strong Buy).</p>
<p>RLI Corporation&#39;s earnings surpassed estimates in three of the last four quarters while missing in one, the average beat being 132.39%. Year to date, shares of RLI have gained 8.2%.</p>
<p>The Zacks Consensus Estimate for RLI&#39;s 2024 and 2025 earnings implies 18.2% and 4.1% year-over-year growth, respectively.</p>
<p>Palomar&#39;s earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 15.10%. Year to date, PLMR&#39;s stock has surged 65.8%.</p>
<p>The Zacks Consensus Estimate for PLMR&#39;s 2024 and 2025 earnings indicates 26.3% and 18.5% year-over-year growth, respectively.</p>
<p>ProAssurance earnings surpassed estimates in two of the last four quarters and missed in the other two. Year to date, PRA&#39;s stock has lost 12.4%.</p>
<p>The Zacks Consensus Estimate for PRA&#39;s 2024 and 2025 earnings implies 371.4% and 72.6% year-over-year growth, respectively.</p>
<p><a href="https://www.zacks.com/stock/news/2305535/here-s-why-wait-see-style-is-apt-for-first-american-faf?cid=CS-BENZ-FT-analyst_blog|rank_focused-2305535">To read this article on Zacks.com click here.</a></p>


PLMR

Here's Why Wait & See Style Is Apt for First American

<p>JMP Securities  analyst Matthew Carletti   maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Market Outperform and lowers the price target from $22 to $20.</p>


JMP Securities Maintains Market Outperform on ProAssurance, Lowers Price Target to $20

<p><strong>Cincinnati Financial Corporation</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cinf#NASDAQ">CINF</a>) higher level of insured exposure, rate increase, agent-focused business model, consistent cash flow and a solid capital position make it worth retaining in one&#39;s portfolio.</p>
<p>It has a solid history of delivering positive surprises in the last five quarters. Earnings of this Zacks Rank #3 (Hold) insurer grew 11.9% in the last five years, better than the industry average of 10.5%.</p>
<p>CINF has a VGM Score of B. The Zacks Consensus Estimate for 2025 earnings per share has moved 1 cent north in the past 30 days, reflecting analyst optimism.</p>
<p>Shares have gained 12.8% year to date, compared with the industry&#39;s increase of 13.9%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d8/70799.jpg?v=624595373" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Return on Equity</h3>
<p>CINF has a return on equity (&quot;ROE&quot;) of 9.3%, better than the industry average of 7.8%. ROE measures how efficiently a company utilizes shareholders&#39; funds to generate profit.</p>
<h3>Optimistic Growth Projection</h3>
<p>The Zacks Consensus Estimate for 2024 earnings stands at $6.32 per share, suggesting an increase of 4.8% on 10.7% higher revenues of $9.8 billion. The consensus estimate for 2025 earnings per share stands at $6.99, suggesting an increase of 10.7% on 8.5% higher revenues of $10.7 billion.</p>
<p>The long-term earnings growth is expected to be 7.3%. We expect the 2026 bottom line to witness a three-year CAGR of 6.5%.</p>
<h3>Business Tailwinds</h3>
<p>Prudent pricing, an agent-centric model, a higher level of insured exposures and disciplined expansion of Cincinnati Re should benefit premiums, the primary driver of an insurer&#39;s top line. We expect 2026 net earned premiums to witness a three-year CAGR of 8.5%. CINF boasts above-average industry premium growth.</p>
<p>The Excess and Surplus line has been performing well since its inception in 2008. This segment should continue to benefit from new business written, higher renewal written premiums and higher average renewal estimated pricing. Technology and data are also being used to identify new exposures in emerging businesses.</p>
<p>Improving interest income from fixed-maturity securities and a decrease in equity portfolio dividends in an improved rate environment should drive net investment income.</p>
<p>Notably, its free cash flow conversion has remained more than 150% over the last many quarters, reflecting its solid earnings.</p>
<h3>Risks</h3>
<p>Despite the upside potential, there are a few factors that investors should keep an eye on.</p>
<p>Being a property and casualty insurer, CINF is exposed to catastrophe losses, inducing volatility in its underwriting profitability. Nonetheless, banking on prudent underwriting, CINF&#39;s solid track record of 34 years of favorable reserve development is appreciable. It also has a reinsurance program to limit insured loss.</p>
<p>CINF has been witnessing an increase in expenses over the past many years due to a rise in insurance loss and policyholder benefits as well as underwriting, acquisition and insurance expenses, resulting in margin contraction. We expect expenses to increase 10.3% in 2024. Net margin is expected to contract 292 basis points in the same year.</p>
<h3>Impressive Dividend History</h3>
<p>Banking on operational efficiency that ensures continuous cash flows, this insurer boasts increasing dividends for 64 straight years. Its dividend yield of 2.8% is better than the industry average of 0.3%, making the stock an attractive pick for yield-seeking investors.&nbsp; Given the board&#39;s positive outlook and confidence in outstanding capital, liquidity and financial flexibility, we expect the momentum to continue.</p>
<h3>Stocks to Consider</h3>
<p>Some top-ranked stocks from the insurance industry are <strong>HCI Group, Inc</strong>. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>), <strong>Palomar Holdings </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>) and <strong>ProAssurance </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>), each sporting a Zacks Rank #1 (Strong Buy).</p>
<p>HCI Group earnings surpassed estimates in each of the last four quarters, the average beat being 139.15%. In the past year, HCI has rallied 45.7%.</p>
<p>The Zacks Consensus Estimate for HCI&#39;s 2024 and 2025 earnings implies 57.6% and 4.3% year-over-year growth, respectively.</p>
<p>Palomar&#39;s earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 15.10%. In the past year, PLMR&#39;s stock has surged 45.5%.</p>
<p>The Zacks Consensus Estimate for PLMR&#39;s 2024 and 2025 earnings indicates 26% and 18% year-over-year growth, respectively.</p>
<p>ProAssurance earnings surpassed estimates in two of the last four quarters and missed in the other two. In the past year, PRA&#39;s stock has lost 28.1%.</p>
<p>The Zacks Consensus Estimate for PRA&#39;s 2024 and 2025 earnings suggests 371.4% and 72.6% year-over-year growth, respectively.</p>
<p><a href="https://www.zacks.com/stock/news/2298723/here-s-why-you-should-retain-cincinnati-financial-cinf-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2298723">To read this article on Zacks.com click here.</a></p>


CINF

Here's Why You Should Retain Cincinnati Financial Stock

<p><strong>RLI Corp.&#39;s</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rli#NYSE">RLI</a>) strong product portfolio, rate increases, improved retention, higher premium receipts and sufficient liquidity make it worth adding to one&#39;s portfolio.</p>
<h3>Optimistic Growth Projections</h3>
<p>The Zacks Consensus Estimate for RLI&#39;s 2024 earnings per share indicates an increase of 18.4% from the year-ago reported number. The consensus estimate for revenues is pegged at $1.64 billion, implying a year-over-year improvement of 15.6%.</p>
<p>The consensus estimate for 2025 earnings per share and revenues indicates an increase of 3.8% and 9.2%, respectively, from the corresponding 2024 estimates.</p>
<p>Earnings have grown 18.7% in the past five years, better than the industry average of 10.5%</p>
<h3>Earnings Surprise History</h3>
<p>RLI has a solid track record of beating earnings estimates in three of the last four quarters while missing in one, the average being 132.39%.</p>
<h3>Estimate Revision</h3>
<p>The Zacks Consensus Estimate for 2024 and 2025 earnings has moved 1.9% and 2.7% north, respectively, in the past 60 days. This should instill investors&#39; confidence in the stock.</p>
<h3>Zacks Rank &amp; Price Performance</h3>
<p>RLI currently carries a Zacks Rank #2 (Buy). Year to date, the stock has gained 4.3% compared with the industry&#39;s growth of 13.5%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c4/70769.jpg?v=233749238" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Business Tailwinds</h3>
<p>Product diversification across the Casualty, Property and Surety segments of the company has fueled the insurer&#39;s growth and financial success. The Casualty segment continues to gain from an expanded distribution base in personal umbrella and rate increases.</p>
<p>The commercial property business has been gaining from higher wind and earthquake exposure rates. Rate increases, improved retention and new opportunities in the inland marine space should benefit marine products.</p>
<p>The Surety segment continues to benefit from its compelling product portfolio, growth within existing accounts and writing of bonds with new customers. Building materials inflation and new accounts will aid commercial and contract surety businesses in the future. RLI boasts solid operating results and its financial position remained strong. Operating cash flows are likely to gain from higher premium receipts.</p>
<p>The insurer has a sound capital structure, helping it meet the interests of its policyholders, enhance operations in the insurance sector and aid growth in its book value for the long term. The insurer&#39;s trailing 12-month return on equity of 17.2% outperforms the industry average of 7.8%. Such a robust capital position provides significant financial flexibility to the operating subsidiaries.</p>
<p>RLI has been paying dividends for 187 consecutive quarters and increased regular dividends in each of the last 48 years at an eight-year (2016-2023) CAGR of 3.9%. In addition, the insurer has been paying special dividends since 2011. Over the past five years, the insurer has returned $816 million to shareholders. RLI has $87.5 million of remaining capacity from the repurchase program.</p>
<h3>Other Stocks to Consider</h3>
<p>Some other top-ranked stocks from the property and casualty insurance industry are <strong>Palomar Holdings, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>), <strong>ProAssurance Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>) and <strong>NMI Holdings Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmih#NASDAQ">NMIH</a>). While Palomar Holdings and ProAssurance sport a Zacks Rank #1 (Strong Buy) each, NMI Holdings currently carries a Zacks Rank #2.</p>
<p>Palomar Holdings earnings surpassed estimates in each of the last four quarters, the average surprise being 15.10%. Year to date, shares of PLMR have jumped 49.4%. The Zacks Consensus Estimate for PLMR&#39;s 2024 and 2025 revenues implies year-over-year growth of 26% and 18.1%, respectively.</p>
<p>The Zacks Consensus Estimate for ProAssurance&#39;s 2024 and 2025 earnings has moved 46.1% and 24.5% north, respectively, in the past 60 days. Year to date, shares of PRA have jumped 4.3%. The Zacks Consensus Estimate for PRA&#39;s 2024 and 2025 revenues implies year-over-year growth of 371.43% and 72.63%, respectively.</p>
<p>NMI Holdings&#39; earnings surpassed estimates in each of the last four quarters, the average surprise being 8.60%. Year to date, shares of NMIH have jumped 14.1%. The Zacks Consensus Estimate for NMIH&#39;s 2024 and 2025 revenues implies year-over-year growth of 10.6% and 7.6%, respectively.</p>
<p><a href="https://www.zacks.com/stock/news/2298454/reasons-why-investors-should-consider-buying-rli-stock-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2298454">To read this article on Zacks.com click here.</a></p>


Reasons Why Investors Should Consider Buying RLI Stock Now

<p><strong>AXIS Capital Holdings Limited </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axs#NYSE">AXS</a>) is poised to gain from its compelling and diversified product portfolio, underwriting excellence, digital capabilities and solid capital position. These, along with solid growth projections, make the stock worth retaining.<br />
This leading specialty insurer and global reinsurer, carrying a Zacks rank #3 (Hold), aiming for leadership in specialty risks, has a VGM Score of B. This helps to identify stocks with the most attractive value, growth and momentum.</p>
<h3>An Outperformer</h3>
<p>Shares of AXS have rallied 25.7% year to date, compared with the industry&#39;s increase of 14.9%, the Finance sector&#39;s rise of 3.8% and the Zacks S&amp;P 500 composite&#39;s rise of 15%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/95/69076.jpg?v=1050739775" /><br />
Image Source: Zacks Investment Research</p>
<h3>Return on Capital</h3>
<p>AXS&#39;s trailing 12-month return on equity is 19.%, ahead of the industry average of 7.8%. Return on equity, a profitability measure, reflects how effectively a company is utilizing its shareholders.<br />
Also, the return on invested capital&nbsp;in the trailing 12 months was 11.1%, better than the industry average of 5.9%. Its ROIC has been increasing over the last few quarters amid capital investment made over the same time frame. This reflects the company&#39;s efficiency in utilizing funds to generate income.</p>
<h3>Northbound Estimates</h3>
<p>The Zacks Consensus Estimate for 2024 and 2025 earnings has moved 1 cent north each in the past seven days, reflecting analyst optimism.</p>
<h3>Optimistic Growth Projection</h3>
<p>The Zacks Consensus Estimate for 2024 earnings is pegged at $10.11, indicating an increase of 2.6% on 4.8% higher revenues of $6 billion. The consensus estimate for 2025 earnings is pegged at $11.01, indicating an increase of 8.9% on 9.1% higher revenues of $6.5 billion. &nbsp;<br />
The expected long-term earnings growth rate is pegged at 27.1%, better than the industry average of 10.2%. We expect 2026 EPS to witness a three-year CAGR of 6.9%.</p>
<h3>Growth Drivers</h3>
<p>AXS&#39;s focus on investing in growth areas, including wholesale insurance and lower middle markets, should drive growth. Exiting the volatile catastrophe and property reinsurance space and reducing risk exposure while concentrating on accident and health, casualty, credit and surety, and specialty reinsurance lines should help AXIS Capital achieve its goal of being a leading specialty underwriter.<br />
While a diversified portfolio of global specialty business, leadership positions and growth opportunities across major business lines drives the Insurance segment, the Reinsurance business should benefit from strong cycle management that focuses on improving the business mix.<br />
AXIS Capital is also working with its distribution partners to use expanding digital capabilities to create new business growth in desirable smaller accounts.</p>
<h3>Risks</h3>
<p>Despite the upside potential, there are a few factors that investors should keep an eye on. AXIS Capital is highly exposed to losses resulting from natural disasters, man-made catastrophes and other catastrophic events, which induce volatility in its underwriting profitability. &nbsp;<br />
This apart, this insurer has been witnessing rising expenses over the last few years due to higher net losses and loss expenses, general and administrative expenses, higher acquisition costs and an increase in interest expense as well as financing costs, which are hurting margins.&nbsp; &nbsp;</p>
<h3>Impressive Dividend History</h3>
<p>Axis Capital has an impressive history of distributing wealth to shareholders via dividends and share buybacks. It hiked its dividend for 18 straight years. Its dividend yield is currently 2.5%, way above the industry average of 0.3%. The insurer boasts one of the highest dividend yields among its peers.</p>
<h3>Stocks to Consider&nbsp;&nbsp; &nbsp;</h3>
<p>Some top-ranked stocks from the insurance industry are <strong>HCI Group, Inc</strong>. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>), <strong>Palomar Holdings </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>) and <strong>ProAssurance </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pra#NYSE">PRA</a>). Each stock presently sports a Zacks Rank #1 (Strong Buy).<br />
HCI Group&#39;s earnings surpassed estimates in each of the last four quarters, the average beat being 139.15%. In the past year, shares of HCI have gained 7.8%.<br />
The Zacks Consensus Estimate for HCI&#39;s 2024 and 2025 earnings implies 57.6% and 4.3% year-over-year growth, respectively.<br />
Palomar&#39;s earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 15.10%. In the past year, PLMR&#39;s stock has surged 45%.<br />
The Zacks Consensus Estimate for PLMR&#39;s 2024 and 2025 earnings indicates 26% and 18% year-over-year growth, respectively.<br />
ProAssurance earnings surpassed estimates in two of the last four quarters and missed in the other two. In the past year, PRA&#39;s stock has lost 9.1%.<br />
The Zacks Consensus Estimate for PRA&#39;s 2024 and 2025 earnings implies 371.4% and 72.6% year-over-year growth, respectively.</p>
<p><a href="https://www.zacks.com/stock/news/2290001/here-s-why-you-should-stay-invested-in-axis-capital-axs?cid=CS-BENZ-FT-analyst_blog|rank_focused-2290001">To read this article on Zacks.com click here.</a></p>


Here's Why You Should Stay Invested in AXIS Capital

<p>In the latest quarter, 5 analysts provided ratings for ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ProAssurance and provided 12-month price targets. The average target is $17.8, accompanied by a high estimate of $22.00 and a low estimate of $14.00. Observing a 4.71% increase, the current average has risen from the previous average price target of $17.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715194838_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of ProAssurance by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ProAssurance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ProAssurance compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for ProAssurance's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of ProAssurance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ProAssurance analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know ProAssurance Better</h2>
<p>ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&amp;C activities, followed by Worker's Compensation.</p>
<h3>Understanding the Numbers: ProAssurance's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> ProAssurance displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.9%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>1.64%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ProAssurance's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.42%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> ProAssurance's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.08%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> ProAssurance's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.4</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From ProAssurance Analyst Ratings

<p>Truist Securities  analyst Mark Hughes   maintains ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) with a Hold and raises the price target from $14 to $16.</p>


Truist Securities Maintains Hold on ProAssurance, Raises Price Target to $16

<p>ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 157.14 percent increase over losses of $(0.14) per share from the same period last year.  The company reported quarterly sales of $244.150 million which missed the analyst consensus estimate of $318.837 million by 23.42 percent.  This is a 1.82 percent increase over sales of $239.787 million the same period last year.</p>


ProAssurance Q1 2024 Adj EPS $0.08 Beats $0.06 Estimate, Sales $244.150M Miss $318.837M Estimate

<p>In the last three months, 5 analysts have published ratings on ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.4, a high estimate of $24.00, and a low estimate of $14.00. This current average has decreased by 1.77% from the previous average price target of $19.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713211302_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of ProAssurance among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ProAssurance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ProAssurance compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ProAssurance's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ProAssurance's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ProAssurance analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About ProAssurance</h2>
<p>ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&amp;C activities, followed by Worker's Compensation.</p>
<h3>Key Indicators: ProAssurance's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> ProAssurance's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-0.05%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.16%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ProAssurance's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.6%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ProAssurance's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.11%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.4</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

ProAssurance

ProAssurance (PRA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga